vs

Side-by-side financial comparison of CARTERS INC (CRI) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $757.8M, roughly 2.0× CARTERS INC). Steris runs the higher net margin — 12.9% vs 1.5%, a 11.4% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs -0.1%). Steris produced more free cash flow last quarter ($199.5M vs $-144.1M).

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

CRI vs STE — Head-to-Head

Bigger by revenue
STE
STE
2.0× larger
STE
$1.5B
$757.8M
CRI
Growing faster (revenue YoY)
STE
STE
+9.2% gap
STE
9.2%
-0.1%
CRI
Higher net margin
STE
STE
11.4% more per $
STE
12.9%
1.5%
CRI
More free cash flow
STE
STE
$343.6M more FCF
STE
$199.5M
$-144.1M
CRI

Income Statement — Q3 FY2026 vs Q3 FY2026

Metric
CRI
CRI
STE
STE
Revenue
$757.8M
$1.5B
Net Profit
$11.6M
$192.9M
Gross Margin
45.1%
43.8%
Operating Margin
3.8%
18.3%
Net Margin
1.5%
12.9%
Revenue YoY
-0.1%
9.2%
Net Profit YoY
-80.1%
11.2%
EPS (diluted)
$0.32
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRI
CRI
STE
STE
Q4 25
$1.5B
Q3 25
$757.8M
$1.5B
Q2 25
$585.3M
$1.4B
Q1 25
$629.8M
$1.5B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.1B
Net Profit
CRI
CRI
STE
STE
Q4 25
$192.9M
Q3 25
$11.6M
$191.9M
Q2 25
$446.0K
$177.4M
Q1 25
$15.5M
$145.7M
Q4 24
$173.5M
Q3 24
$150.0M
Q2 24
$145.4M
Q1 24
$-1.4M
Gross Margin
CRI
CRI
STE
STE
Q4 25
43.8%
Q3 25
45.1%
44.2%
Q2 25
48.1%
45.1%
Q1 25
46.2%
43.3%
Q4 24
44.5%
Q3 24
43.6%
Q2 24
44.7%
Q1 24
40.2%
Operating Margin
CRI
CRI
STE
STE
Q4 25
18.3%
Q3 25
3.8%
18.2%
Q2 25
0.7%
17.7%
Q1 25
4.1%
14.6%
Q4 24
17.9%
Q3 24
16.5%
Q2 24
14.5%
Q1 24
22.0%
Net Margin
CRI
CRI
STE
STE
Q4 25
12.9%
Q3 25
1.5%
13.1%
Q2 25
0.1%
12.8%
Q1 25
2.5%
9.8%
Q4 24
12.7%
Q3 24
11.3%
Q2 24
11.4%
Q1 24
-0.1%
EPS (diluted)
CRI
CRI
STE
STE
Q4 25
$1.96
Q3 25
$0.32
$1.94
Q2 25
$0.01
$1.79
Q1 25
$0.43
$1.48
Q4 24
$1.75
Q3 24
$1.51
Q2 24
$1.46
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRI
CRI
STE
STE
Cash + ST InvestmentsLiquidity on hand
$184.2M
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$864.6M
$7.2B
Total Assets
$2.5B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRI
CRI
STE
STE
Q4 25
$423.7M
Q3 25
$184.2M
$319.2M
Q2 25
$338.2M
$279.7M
Q1 25
$320.8M
$171.7M
Q4 24
$155.2M
Q3 24
$172.2M
Q2 24
$198.3M
Q1 24
$207.0M
Total Debt
CRI
CRI
STE
STE
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
CRI
CRI
STE
STE
Q4 25
$7.2B
Q3 25
$864.6M
$7.0B
Q2 25
$853.9M
$7.0B
Q1 25
$847.2M
$6.6B
Q4 24
$6.4B
Q3 24
$6.6B
Q2 24
$6.4B
Q1 24
$6.3B
Total Assets
CRI
CRI
STE
STE
Q4 25
$10.6B
Q3 25
$2.5B
$10.4B
Q2 25
$2.5B
$10.4B
Q1 25
$2.3B
$10.1B
Q4 24
$10.0B
Q3 24
$10.2B
Q2 24
$10.1B
Q1 24
$11.1B
Debt / Equity
CRI
CRI
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRI
CRI
STE
STE
Operating Cash FlowLast quarter
$-128.0M
$298.2M
Free Cash FlowOCF − Capex
$-144.1M
$199.5M
FCF MarginFCF / Revenue
-19.0%
13.3%
Capex IntensityCapex / Revenue
2.1%
6.6%
Cash ConversionOCF / Net Profit
-11.04×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRI
CRI
STE
STE
Q4 25
$298.2M
Q3 25
$-128.0M
$287.8M
Q2 25
$40.3M
$420.0M
Q1 25
$-48.6M
$260.8M
Q4 24
$332.8M
Q3 24
$250.7M
Q2 24
$303.7M
Q1 24
$254.8M
Free Cash Flow
CRI
CRI
STE
STE
Q4 25
$199.5M
Q3 25
$-144.1M
$201.3M
Q2 25
$24.1M
$326.4M
Q1 25
$-59.0M
$189.9M
Q4 24
$243.6M
Q3 24
$148.8M
Q2 24
$195.7M
Q1 24
$163.3M
FCF Margin
CRI
CRI
STE
STE
Q4 25
13.3%
Q3 25
-19.0%
13.8%
Q2 25
4.1%
23.5%
Q1 25
-9.4%
12.8%
Q4 24
17.8%
Q3 24
11.2%
Q2 24
15.3%
Q1 24
14.6%
Capex Intensity
CRI
CRI
STE
STE
Q4 25
6.6%
Q3 25
2.1%
5.9%
Q2 25
2.8%
6.7%
Q1 25
1.6%
4.8%
Q4 24
6.5%
Q3 24
7.7%
Q2 24
8.4%
Q1 24
8.2%
Cash Conversion
CRI
CRI
STE
STE
Q4 25
1.55×
Q3 25
-11.04×
1.50×
Q2 25
90.37×
2.37×
Q1 25
-3.13×
1.79×
Q4 24
1.92×
Q3 24
1.67×
Q2 24
2.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons